Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog

INTRODUCTION: Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment. We aimed to investigate the impact of aspirin on reducing HCC risk in patients treated with first-line oral nucleos(t)ide analogs (NAs; entecavir a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Vicki Wing-Ki, Yip, Terry Cheuk-Fung, Wong, Vincent Wai-Sun, Tse, Yee-Kit, Chan, Henry Lik-Yuen, Lui, Grace Chung-Yan, Wong, Grace Lai-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126482/
https://www.ncbi.nlm.nih.gov/pubmed/33750746
http://dx.doi.org/10.14309/ctg.0000000000000324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126482/
https://www.ncbi.nlm.nih.gov/pubmed/33750746
http://dx.doi.org/10.14309/ctg.0000000000000324

Ejemplares similares